Skip to main content

Table 1 Demographic characteristics and clinical data of the study cohort at baseline

From: Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population

Number of patients

201

Men/female, n

150:51

Age, years ± SD

74.9 ± 8.9

Diabetes duration, years ± SD

11.4 ± 0.8

BMI, Kg/m2 ± SD

26.7 ± 0.6

Smoking (current), n (%)

103 (51.2)

Smoking (former), n (%)

68 (33.8)

Never smoked, n (%)

31 (15.4)

Hypertension, n (%)

146 (72.6)

Hypercholesterolemia, n (%)

109 (54.2)

CAD, n (%)

93 (46.3)

CVD, n (%)

99 (49.2)

Oral antidiabetic agents, n (%)

89 (44.3)

Insulin, n (%)

147 (73.1)

ABI, ± SD

0.6 ± 0.1

Rutherford II-4, n (%)

109 (54.2)

Rutherford III-5, n (%)

92 (45.8)

WIfI010, n (%)

61 (30.3)

WIfI020, n (%)

51 (25.4)

WIfI110, n (%)

49 (24.4)

WIfI120, n (%)

40 (19.9)

HbA1c, % ± SD

8.9 ± 0.7

FBG, mg/dL ± SD

127.9 ± 9.7

Total cholesterol, mg/dL ± SD

218.9 ± 22.3

LDL cholesterol, mg/dL ± SD

112.4 ± 15.4

Triglycerides, mg/dL ± SD

172.5 ± 8.5

eGFR, mL/min/1.73m2 ± SD

72.6 ± 10.5

HMGB-1, ng/mL ± SD

5.9 ± 2.7

  1. Data are reported as means (standard deviation) for continuous variables and numbers (percentages) for categorical variables
  2. BMI, body mass index; CAD, coronary artery disease; CVD, cerebrovascular disease; ABI, ankle brachial index; WIfI, wound, ischemia, foot infection; FBG, fasting blood glucose; eGFR, estimated glomerular filtration rate; HMGB-1, high mobility group box 1